Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $8.07 USD
Change Today -0.07 / -0.86%
Volume 39.5K
As of 10:54 AM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

akebia therapeutics inc (AKBA) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/20/14 - $31.00
52 Week Low
05/7/15 - $7.27
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

akebia therapeutics inc (AKBA) Related Businessweek News

No Related Businessweek News Found

akebia therapeutics inc (AKBA) Details

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor (HIF) biology for patients with kidney disease. Its lead product candidate is AKB-6548, an oral therapy which has completed a Phase 2b study for the treatment of anemia related to chronic kidney disease in non-dialysis patients, as well as tested in a Phase 2 study for the treatment of anemia in patients undergoing dialysis. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

41 Employees
Last Reported Date: 03/4/15
Founded in 2007

akebia therapeutics inc (AKBA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $552.3K
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $415.9K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $181.5K
Compensation as of Fiscal Year 2014.

akebia therapeutics inc (AKBA) Key Developments

Akebia Therapeutics, Inc. Announces Unaudited Earnings Results for the First Quarter Ended March 31, 2015

Akebia Therapeutics, Inc. announced unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported operating loss of USD 10,896,000 against USD 9,909,000 a year ago. Net loss applicable to common shareholders was USD 10,695,000 or USD 0.53 per basic and diluted share against USD 96,597,000 or USD 43.37 per basic and diluted share a year ago. Cash used in operations was USD 8.3 million, an increase of USD 2.3 million from USD 6.0 million for the same period of 2014.

Akebia Therapeutics, Inc. Presents at UBS Global Healthcare Conference, May-18-2015 09:30 AM

Akebia Therapeutics, Inc. Presents at UBS Global Healthcare Conference, May-18-2015 09:30 AM. Venue: Sheraton New York Times Square Hotel, 811 Seventh Avenue, New York, New York, United States. Speakers: John P. Butler, Chief Executive Officer, President and Director.

Akebia Therapeutics Seeks Acquisitions

Akebia Therapeutics, Inc. (NasdaqGM:AKBA) has filed a shelf registration in the amount of $175 million. Akebia Therapeutics said, "We intend to use the net proceeds we receive from our sale of the securities covered by this prospectus for general corporate purposes, which may include working capital, capital expenditures, research and development expenditures, clinical trial expenditures, commercial expenditures, and possible acquisitions or in-licenses of product candidates."


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AKBA:US $8.07 USD -0.07

AKBA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AKBA.
View Industry Companies

Industry Analysis


Industry Average

Valuation AKBA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AKEBIA THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at